Compare OSS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | BIVI |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.3M | 8.5M |
| IPO Year | 2017 | 2013 |
| Metric | OSS | BIVI |
|---|---|---|
| Price | $7.72 | $1.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 62.4K |
| Earning Date | 03-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $37,027,382.00 | N/A |
| Revenue This Year | $13.57 | N/A |
| Revenue Next Year | $23.40 | N/A |
| P/E Ratio | $38.82 | ★ N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $1.85 | $0.62 |
| 52 Week High | $12.75 | $9.09 |
| Indicator | OSS | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 53.27 |
| Support Level | $4.78 | $1.21 |
| Resistance Level | $12.48 | $1.52 |
| Average True Range (ATR) | 0.95 | 0.11 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 1.87 | 56.25 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bressner segment.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.